BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
Europe - FRA:BSX - US1011371077 - Common Stock
82.8 EUR
-1.2 (-1.43%)
Overall BSX gets a fundamental rating of 5 out of 10. We evaluated BSX against 58 industry peers in the Health Care Equipment & Supplies industry. BSX has only an average score on both its financial health and profitability. BSX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year BSX was profitable.
BSX had a positive operating cash flow in the past year.
BSX had positive earnings in 4 of the past 5 years.
BSX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.03%, BSX is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
BSX has a better Return On Equity (11.17%) than 70.69% of its industry peers.
BSX has a better Return On Invested Capital (7.66%) than 68.97% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BSX is below the industry average of 8.65%.
The 3 year average ROIC (6.54%) for BSX is below the current ROIC(7.66%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROIC | 7.66% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1.3 Margins
The Profit Margin of BSX (13.54%) is better than 79.31% of its industry peers.
BSX's Profit Margin has declined in the last couple of years.
The Operating Margin of BSX (18.69%) is better than 81.03% of its industry peers.
BSX's Operating Margin has been stable in the last couple of years.
BSX has a better Gross Margin (68.30%) than 75.86% of its industry peers.
BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% |
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BSX has more shares outstanding
The number of shares outstanding for BSX has been increased compared to 5 years ago.
The debt/assets ratio for BSX is higher compared to a year ago.
2.2 Solvency
BSX has an Altman-Z score of 5.50. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.50, BSX belongs to the best of the industry, outperforming 91.38% of the companies in the same industry.
BSX has a debt to FCF ratio of 3.33. This is a good value and a sign of high solvency as BSX would need 3.33 years to pay back of all of its debts.
The Debt to FCF ratio of BSX (3.33) is better than 77.59% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that BSX is not too dependend on debt financing.
BSX's Debt to Equity ratio of 0.50 is in line compared to the rest of the industry. BSX outperforms 44.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Altman-Z | 5.5 |
ROIC/WACC0.92
WACC8.29%
2.3 Liquidity
BSX has a Current Ratio of 1.37. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.37, BSX perfoms like the industry average, outperforming 43.10% of the companies in the same industry.
BSX has a Quick Ratio of 1.37. This is a bad value and indicates that BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.82, BSX is not doing good in the industry: 63.79% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.91% over the past year.
The Earnings Per Share has been growing by 9.56% on average over the past years. This is quite good.
The Revenue has grown by 21.45% in the past year. This is a very strong growth!
Measured over the past years, BSX shows a quite strong growth in Revenue. The Revenue has been growing by 9.30% on average per year.
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
3.2 Future
BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.08% yearly.
Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 11.70% on average per year.
EPS Next Y20.01%
EPS Next 2Y16.91%
EPS Next 3Y15.57%
EPS Next 5Y14.08%
Revenue Next Year19.6%
Revenue Next 2Y15.24%
Revenue Next 3Y13.53%
Revenue Next 5Y11.7%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 34.36, the valuation of BSX can be described as expensive.
BSX's Price/Earnings is on the same level as the industry average.
BSX's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.06.
Based on the Price/Forward Earnings ratio of 28.37, the valuation of BSX can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as BSX.
BSX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.64, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.36 | ||
| Fwd PE | 28.37 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BSX is valued a bit more expensive than the industry average as 62.07% of the companies are valued more cheaply.
BSX's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.4 | ||
| EV/EBITDA | 32.98 |
4.3 Compensation for Growth
BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
BSX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BSX's earnings are expected to grow with 15.57% in the coming years.
PEG (NY)1.72
PEG (5Y)3.59
EPS Next 2Y16.91%
EPS Next 3Y15.57%
5. Dividend
5.1 Amount
BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BSX (9/25/2025, 7:00:00 PM)
82.8
-1.2 (-1.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.45%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap122.69B
Analysts85
Price Target106.23 (28.3%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.53%
Min EPS beat(2)2.49%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)6.23%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.12%
EPS beat(12)11
Avg EPS beat(12)5.14%
EPS beat(16)15
Avg EPS beat(16)4.28%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)2.15%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.1%
Revenue beat(12)11
Avg Revenue beat(12)2.01%
Revenue beat(16)12
Avg Revenue beat(16)1.41%
PT rev (1m)-1.74%
PT rev (3m)0.91%
EPS NQ rev (1m)-0.09%
EPS NQ rev (3m)2.36%
EPS NY rev (1m)0%
EPS NY rev (3m)2.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.36 | ||
| Fwd PE | 28.37 | ||
| P/S | 7.8 | ||
| P/FCF | 41.4 | ||
| P/OCF | 33.67 | ||
| P/B | 6.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | 32.98 |
EPS(TTM)2.41
EY2.91%
EPS(NY)2.92
Fwd EY3.52%
FCF(TTM)2
FCFY2.42%
OCF(TTM)2.46
OCFY2.97%
SpS10.62
BVpS12.87
TBVpS-1.68
PEG (NY)1.72
PEG (5Y)3.59
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROCE | 9.51% | ||
| ROIC | 7.66% | ||
| ROICexc | 7.77% | ||
| ROICexgc | 26.52% | ||
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% | ||
| FCFM | 18.84% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexcg growth 3Y8.56%
ROICexcg growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 60.84% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 89.77% | ||
| Profit Quality | 139.08% | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | 5.5 |
F-Score5
WACC8.29%
ROIC/WACC0.92
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
EPS Next Y20.01%
EPS Next 2Y16.91%
EPS Next 3Y15.57%
EPS Next 5Y14.08%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
Revenue Next Year19.6%
Revenue Next 2Y15.24%
Revenue Next 3Y13.53%
Revenue Next 5Y11.7%
EBIT growth 1Y26.44%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year35.67%
EBIT Next 3Y20.23%
EBIT Next 5Y14.94%
FCF growth 1Y131.03%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y101.7%
OCF growth 3Y22.44%
OCF growth 5Y13.34%